Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.06 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.05 -0.01 (-0.94%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Earnings News For KPTI
-
Karyopharm Therapeutics: Q4 Earnings Snapshot
-
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
-
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
-
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
-
Karyopharm Therapeutics: Q3 Earnings Snapshot
-
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics: Q2 Earnings Snapshot
-
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics: Q1 Earnings Snapshot
-
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
-
Will Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should Know
-
Karyopharm Therapeutics: Q4 Earnings Snapshot
-
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Misses Revenue Estimates
-
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
-
Analysts Estimate Karyopharm Therapeutics (KPTI) to Report a Decline in Earnings: What to Look Out for
-
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics: Q3 Earnings Snapshot
-
Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
-
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics: Q2 Earnings Snapshot
-
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates
-
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
-
Karyopharm Therapeutics (KPTI) Tops Q4 Earnings and Revenue Estimates